Sulfonium‐Stapled Peptides‐Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention
Source abstract
Abstract
Abstract Neoantigen peptides hold great potential as vaccine candidates for tumor immunotherapy. However, due to the limitation of antigen cellular uptake and cross‐presentation, the progress with neoantigen peptide‐based vaccines has obviously lagged in clinical trials. Here, a stapling peptide‐based nano‐vaccine is developed, comprising a self‐assembly nanoparticle driven by the nucleic acid adjuvant‐antigen conjugate. This nano‐vaccine stimulates a strong tumor‐specific T cell response by activating antigen presentation and toll‐like receptor signaling pathways. By markedly improving the efficiency of antigen/adjuvant co‐delivery to the draining lymph nodes, the nano‐vaccine leads to 100% tumor prevention for up to 11 months and without tumor recurrence, heralding the generation of long‐term anti‐tumor memory. Moreover, the injection of nano‐vaccine with signal neoantigen eliminates the established MC‐38 tumor (a cell line of murine carcinoma of the colon without exogenous OVA protein expression) in 40% of the mice by inducing potent cytotoxic T lymphocyte infiltration in the tumor microenvironment without substantial systemic toxicity. These findings represent that stapling peptide‐based nano‐vaccine may serve as a facile, general, and safe strategy to stimulate a strong anti‐tumor immune response for the neoantigen peptide‐based personalized tumor immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pingshan Translational Medicine Center Shenzhen Bay Laboratory Shenzhen 518055 P. R. China
State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology Peking University Shenzhen Graduate School Shenzhen 518055 P. R. China
NeoCura Bio‐Medical Technology Co. Ltd. Shenzhen 518055 P. R. China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Shenzhen Fundamental Research Program · Natural Science Foundation of Guangdong Province
References (45)
Show source-provided references
1. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
2. 10.1200/JCO.2019.37.15_suppl.252310.1200/JCO.2019.37.15_suppl.2523 ↗
3. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
4. 10.1038/nmat482210.1038/nmat4822 ↗
5. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
6. 10.1038/nature2143310.1038/nature21433 ↗
7. 10.1021/acs.chemrev.9b0047210.1021/acs.chemrev.9b00472 ↗
8. 10.1038/nature2299110.1038/nature22991 ↗
9. 10.1038/s41586-021-04232-510.1038/s41586-021-04232-5 ↗
10. 10.1038/s41551-021-00698-w10.1038/s41551-021-00698-w ↗
11. 10.1021/acsnano.2c0970810.1021/acsnano.2c09708 ↗
12. 10.1084/jem.2017104610.1084/jem.20171046 ↗
13. 10.1158/2326-6066.CIR-18-068610.1158/2326-6066.CIR-18-0686 ↗
14. 10.1038/s41467-017-01386-710.1038/s41467-017-01386-7 ↗
15. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
16. 10.1002/advs.20190010110.1002/advs.201900101 ↗
17. 10.1038/s41573-021-00163-y10.1038/s41573-021-00163-y ↗
18. 10.1111/j.0105-2896.2004.00149.x10.1111/j.0105-2896.2004.00149.x ↗
19. 10.1038/s41573-020-0075-710.1038/s41573-020-0075-7 ↗
20. 10.1038/s41587-022-01294-210.1038/s41587-022-01294-2 ↗
21. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
22. 10.1039/C8MH00392K10.1039/C8MH00392K ↗
23. 10.1016/j.cclet.2020.09.05410.1016/j.cclet.2020.09.054 ↗
24. 10.1021/acs.bioconjchem.8b0090310.1021/acs.bioconjchem.8b00903 ↗
25. 10.1038/s41557-021-00866-010.1038/s41557-021-00866-0 ↗
26. 10.1021/bc015508l10.1021/bc015508l ↗
27. 10.1039/C5CS00889A10.1039/C5CS00889A ↗
28. 10.31635/ccschem.020.20200028310.31635/ccschem.020.202000283 ↗
29. 10.1021/acsami.9b2017810.1021/acsami.9b20178 ↗
30. 10.1038/s41541-020-00253-910.1038/s41541-020-00253-9 ↗
31. 10.1021/acsnano.0c0506210.1021/acsnano.0c05062 ↗
32. 10.1080/2162402X.2021.202325510.1080/2162402X.2021.2023255 ↗
33. 10.1073/pnas.190280511610.1073/pnas.1902805116 ↗
34. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
35. 10.1021/acsnano.9b0552110.1021/acsnano.9b05521 ↗
36. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
37. 10.1002/advs.20200350410.1002/advs.202003504 ↗
38. 10.1073/pnas.200579411710.1073/pnas.2005794117 ↗
39. Cubillos‐Ruiz J. R. · J. Clin. Invest. · 2009 · 119 · 2231
40. 10.1038/ni.186310.1038/ni.1863 ↗
41. 10.1002/eji.183021113610.1002/eji.1830211136 ↗
42. 10.1038/nbt.234410.1038/nbt.2344 ↗
43. 10.1016/j.immuni.2021.11.00110.1016/j.immuni.2021.11.001 ↗
44. 10.1016/j.cell.2020.08.05310.1016/j.cell.2020.08.053 ↗
45. 10.1016/j.ccell.2022.08.00310.1016/j.ccell.2022.08.003 ↗